Instructions for Ascoril Mono (Bromhexine) 4 mg 20 pills
Pack quantity 20 pcs
Minimum storage temperature allowed, °C 25 °C
Maximum storage temperature allowed, °C 10 °C
Best before date 3 months
Round flat-cylindrical tablets in white or almost white with chamfer and risk.
Active substance: bromhexine hydrochloride - 4.00 mg.
Auxiliary substances: lactose monohydrate (dairy sugar) - 80.23 mg, corn starch - 11.54 mg, povidon K-25 - 3.46 mg, magnesium stearate - 0.77 mg.
- Acute and chronic bronchopulmonary diseases accompanied by difficulty in the withdrawal of the sputum:
- bronchitis of different etiology (including bronchiectases),
- bronchial asthma,
- pulmonary tuberculosis,
- pulmonary emphysema,
- pneumonia (acute and chronic),
- cystic fibrosis.
- Rehabilitation of bronchial tree in the pre-operative period and during the treatment and diagnostic intra-bronchial
- manipulations, prevention of accumulation in bronchial tubes of thick viscous sputum after the operation.
Method of use and doses Ascoril:
Inside, no matter how much you eat.
Adults and children over 14 years old - 8-16 mg (2-4 tablets) 3-4 times a day.
Children from 6 to 14 years old - 8 mg (2 tablets) 3 times a day.
Children from 3 to 6 years - four mg (1 tablet) 3 times a day.
The therapeutic effect may appear on the 4-6 day of treatment.
The course of treatment is from four to 28 days.
In case of kidney failure or severe liver disease, you should increase the intervals between treatments or reduce the dose. You should consult your doctor on this matter.
It is recommended to use enough fluids during treatment to maintain the secretolytic effect of bromohexin.It is not recommended to take more than four to five days without a doctor's consultation.
If the improvement does not occur during the treatment period or the symptoms become worse or new symptoms appear, consult your doctor.U
se the drug only according to the indications, the method of use and the doses specified in the instructions
Pharmacological effect Ascoril:
Mucolytic (secretolytic) agent has a expectorant and weak anti-cough effect. Reduces the viscosity of sputum (depolymerizes the mucoprotein and mucopolysaccharide fibers, increases the serous component of bronchial secretion), activates the atrial fibrillation, increases the volume and improves the release of sputum. It stimulates the production of an endogenous surfactant that provides stability of alveolar cells during respiration. The effect manifests itself two to five days after the beginning of treatment.